Buy one course and choose another for free | Offer expires July 12th

Immunogenomics: Understanding the immune response to disease

This is an advanced-level course that explores the molecular and genetic basis of cancer, its evolution and immunology.


Starts 13th July 2024

About This Course

This advanced course is designed to help learners understand the complex and cutting-edge concepts in immunogenomics. It is well-acknowledged that managing diseases such as cancer and autoimmune diseases is difficult using traditional therapeutic approaches. Genetics is linked to diseases and our immune system forms the first line of protection against disease. This course helps to understand the complex interplay of genetic changes driving diseases, particularly cancer and the immune response elicited by the body. The concept of immunotherapy stems from this understanding. The course provides insight into the development of immunotherapies and the role of biomarkers in immunotherapy. The course is aimed to deliver a comprehensive overview of how immunotherapies such as CAR-T therapy work within the body, their clinical applications, and other practical aspects such as adverse and side effects. The program also provides a list of relevant research papers and discusses the career opportunities in this field and the key companies involved in immunogenomics.

Who Is This Course For

This course is designed for a wide range of professionals, with a background in basic bioscience, oncology, genetics, immunology, or any associated field, and capable of self-learning. Undergraduate or graduates and postgraduate scholars, researchers, academicians such as lecturers and professors, policymakers, and other industry professionals who are looking to learn Immunogenomics as a subject are likely to benefit from this course. The course mentions selected research papers published in reputed and peer-reviewed international journals which will be useful to researchers working in this field. Those looking for career opportunities in the field of immunogenomics will also benefit from the course.

What you'll learn

  • Learn about the genetic basis of cancer and the immune response elicited by the body
  • Understand the mechanisms of antigen presentation, immune activation, and exhaustion
  • Explore the role of cancer biomarkers in developing immunotherapies
  • Develop a strong understanding of concepts such as immunogenotyping and immunophenotyping
  • Learn about the development of CAR-T therapies, their mechanism of action, clinical applications, and side effects

Course Content

Expand All

Meet Your Instructor

Dr. Christos Evangelou

Ph.D. in Cancer Biology, Division of Molecular and Clinical Cancer Sciences, University of Manchester, UK. Areas of expertise include cancer immunology, melanoma research, cancer immunotherapy, and mechanisms of immunotherapy resistance. During my Ph.D. research, I studied the role of chronic inflammation and cytokine IFN-gamma in adaptation and immunotherapy resistance in melanoma. By integrating high-throughput transcriptomic analyses and employing various cancer cell lines and animal models, I have developed methods to predict response to immunotherapy in melanoma patients. During my research, I have used the CRISPR/Cas9 system to knockout genes in human and mouse cell lines to assess the role of certain genes in immunotherapy resistance in melanoma.

Dr. Veronica Hughes

Veronica Hughes received her Ph.D. in medical science from the University of Florida. Her primary interest was cancer metastasis, dysregulation of the tumour microenvironment, and analysis of clinical trial design. Additionally, she engaged in the development of novel small animal models.

Dr. Matthias Schröder

Ph.D. in Immunology at the Division of Immunopharmacology of the University Clinic of Frankfurt am Main. Involved in basic and applied research for immunological interventions to treat cancer for 13 years. Matthias used a high-throughput CRISPR/Cas9 approach to generate a library of knockout cells that could be differentiated into immunosuppressive cells to investigate the potential loss of function situations. Currently involved in the development of fusion proteins to activate receptors of the TNF-superfamily (CD40, CD27, etc.) at a small German Biotech company as Head of Assay Development.

Our Partners

We are proud to partner with the leading In2scienceUK as a step towards achieving our mission of imparting quality education and knowledge across the globe.

Interested In This Course For Your Organisation?

Train your employees and/or students in the most in demand topics, with CBEHx for Business and School.

Upskill your organisation with CBEHx for Business and witness your company grow and succeed with online learning support.

The CBEHx for School domain empowers universities, schools, and other educational organizations with career-targeted transformative knowledge and skill development programs.

Common articles

Do you have any question? Please visit our Help Centre

Grow better with the right option, click here to view pricing. 

Usually, there are no general prerequisites when enrolling for any individual courses on However, some courses are certainly more advanced than others that are of introductory and intermediate level. For advanced-level courses, prior knowledge on the topic will be helpful for understanding complex concepts but not mandatory.

The relevant information about the suggested knowledge and background that might be helpful to follow each course is provided on the respective course registration page.

Yes, the courses are flexible and self-paced to suit your schedule. The term “self-paced” implies that the courses do not follow a pre-assigned schedule for learning within the course duration. You will be able to access all the course materials for each course that you have enrolled in as soon as the course begins.

The course completion certificate is CPD accredited. For more informations please visit